Qiagen (NYSE:QGEN) Upgraded to “Outperform” by Wolfe Research

Wolfe Research upgraded shares of Qiagen (NYSE:QGEN) from a peer perform rating to an outperform rating in a research report released on Thursday, MarketBeat Ratings reports. They currently have $50.00 target price on the stock.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. boosted their price objective on shares of Qiagen from $52.00 to $54.00 and gave the stock an overweight rating in a research note on Tuesday, June 18th. Stifel Nicolaus decreased their price objective on Qiagen from $55.00 to $45.00 and set a hold rating for the company in a report on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $51.05.

Qiagen Trading Up 0.9 %

NYSE QGEN opened at $41.11 on Thursday. The company’s 50-day simple moving average is $43.21 and its two-hundred day simple moving average is $43.58. Qiagen has a one year low of $34.74 and a one year high of $47.70. The company has a market capitalization of $9.38 billion, a price-to-earnings ratio of 27.57, a price-to-earnings-growth ratio of 3.15 and a beta of 0.42. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.45 and a current ratio of 1.84.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Monday, April 29th. The company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. Qiagen had a net margin of 17.38% and a return on equity of 12.59%. The company had revenue of $459.00 million during the quarter, compared to the consensus estimate of $453.91 million. During the same quarter in the previous year, the firm posted $0.53 earnings per share. Qiagen’s revenue for the quarter was down 5.4% compared to the same quarter last year. Equities analysts forecast that Qiagen will post 2.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Qiagen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Riverview Trust Co acquired a new stake in Qiagen during the first quarter worth about $28,000. Tower Research Capital LLC TRC grew its stake in shares of Qiagen by 66.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 710 shares of the company’s stock worth $31,000 after purchasing an additional 283 shares during the period. Park Place Capital Corp purchased a new position in shares of Qiagen during the 1st quarter valued at approximately $36,000. Quarry LP acquired a new position in shares of Qiagen in the 4th quarter valued at $38,000. Finally, Toronto Dominion Bank purchased a new stake in Qiagen during the third quarter worth $41,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.